Valion Bio VBIO Insider Ownership

Updated Oct 10, 2026

Over the past year, VBIO insiders bought $28,408 of stock on the open market and sold none.

• By number of insiders, Valion Bio saw 2 insiders buy on the open market over the past 12 months and none sell.
• Among Valion Bio insiders, Christina Rizopoulos Valauri (Director) led open-market buying over the past 12 months with $18,008 of purchases; the latest was on April 1, 2026.
• The latest open-market trade in VBIO stock by an insider was a purchase for $10,400 by Sheryle Bolton (Director) on April 15, 2026.
• According to Business Quant data, insiders at Valion Bio reported 2.94K shares in total in their latest Form 4 filings, or 1.77% of the 166.08K shares outstanding; that total is up 0.07% from 2.93K shares (split-adjusted) at the end of Q2 2026 and up 138.70% from 1.23K shares (split-adjusted) at the end of Q3 2025.
• All of the 2.94K shares held by Valion Bio insiders are held directly, none through trusts, partnerships or other entities.
• Business Quant counts 5 insiders with holdings in Valion Bio stock, among the officers, directors and 10% owners who have filed a Form 4 in the past two years.
• Valion Bio's three largest insider shareholders, based on their latest Form 4 filings, are Jennifer Ernst (Chief Executive Officer, 1.31K shares), Christina Rizopoulos Valauri (Director, 760 shares) and Michael K. Handley (Chief Executive Officer, 441 shares).
• The holding of Jennifer Ernst makes up 44.55% of all shares held by Valion Bio insiders.
• Over the trailing 12 months, 7 insiders reported transactions in VBIO stock across 11 Form 4 filings.
• The insider data for VBIO reflects Form 4 filings through September 24, 2026.